Pharmacogenomic and Circulating Biomarkers for CDK4/6 Inhibitors

Plain-language summary

This study examines how genetic characteristics and blood biomarkers relate to treatment in patients who will receive a CDK4/6 inhibitor for breast cancer. It can include women over 18 who have been diagnosed with breast cancer and have an indication for CDK4/6 inhibitor treatment. This is a non-phase study and is enrolling participants by invitation.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Enrolling by invitation

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Intervention

Whole gene sequencing, Drug-drug interaction analysis, Biomarker analysis

Start date

10/10/2025

Estimated completion

9/1/2028

Countries

Canada

Related genes

Locations

• London, Canada

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* female
* breast cancer diagnosis
* over 18 years of age
* indication for a CDK4/6 inhibitor treatment
* proficient in English

Exclusion Criteria:

* None